64Cu-Labeled Affibody Molecules for Imaging of HER2 Expressing Tumors

Molecular Imaging and Biology

Volumn 12, Issue 3, 2010, Pages 316-324

  Cheng, Zhen ^a   De Jesus, Omayra Padilla ^b   Kramer, Daniel J ^b   De, Abhijit ^a   Webster, Jack M ^b   Gheysens, Olivier ^a   Levi, Jelena ^a   Namavari, Mohammad ^a   Wang, Sen ^a   Park, Jinha Mark ^a   Zhang, Rong ^b   Liu, Hongguang ^a   Lee, Brian ^b   Syud, Faisal A ^b   Gambhir, Sanjiv Sam ^a  

^a STANFORD UNIVERSITY   (United States)

^b GENERAL ELECTRIC COMPANY   (United States)

Author keywords

64Cu; Affibody; HER2; Imaging; PET

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7 TRIS(ACETIC ACID) 10 ACETATE MONO(N ETHYLMALEIMIDE); CHELATING AGENT; COPPER 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID (ZHER2:477)2 CONJUGATE CU 64; COPPER 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID ZHER2:477 CONJUGATE CU 64; DIMER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOMER; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; COPPER; DIAGNOSTIC AGENT; HER2 PROTEIN, HUMAN; HYBRID PROTEIN; ORGANOMETALLIC COMPOUND;

ANIMAL EXPERIMENT; ANTIBODY AFFINITY; ANTIGEN BINDING; ARTICLE; BINDING SITE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DOSIMETRY; FEMALE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; ISOTOPE LABELING; MOLECULAR PROBE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOISOTOPE DISTRIBUTION; TUMOR DIAGNOSIS; TUMOR LOCALIZATION; ANIMAL; CHEMISTRY; DRUG SCREENING; METABOLISM; METHODOLOGY; NEOPLASM; STAINING; SYNTHESIS; TIME; TISSUE DISTRIBUTION; TUMOR CELL LINE; WESTERN BLOTTING;

MUS; MUS MUSCULUS;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; COPPER RADIOISOTOPES; HUMANS; MICE; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; STAINING AND LABELING; TIME FACTORS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956685968     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-009-0256-6     Document Type: Article

References (33)

1. Nygren PA, Skerra A (2004) Binding proteins from alternative scaffolds. J Immunol Methods 290:3-28
2. Binz HK, Amstutz P, Pluckthun A (2005) Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 23:1257-1268
3. Binz HK, Pluckthun A (2005) Engineered proteins as specific binding reagents. Curr Opin Biotechnol 16:459-469
4. Nilsson FY, Tolmachev V (2007) Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Devel 10:167-175
5. Cortez-Retamozo V, Backmann N, Senter PD et al (2004) Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 64:2853-2857
6. Meric-Bernstam F, Hung MC (2006) Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res 12:6326-6330
7. Robert NJ, Favret AM (2007) HER2-positive advanced breast cancer. Hematol Oncol Clin North Am 21:293-302
8. Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F (2007) HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 19:56-62
9. 18F-labeled protein scaffold molecules. J Nucl Med 49:804-813
10. 18F]fluorobenzaldehyde via oxime chemistry. Mol Imaging Biol 10:177-181
11. 18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 35:1008-1018
12. 99mTc to tumor-targeting affibody molecules. Bioconjug Chem 18:549-558
13. 99mTc- chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging 34:722-733
14. Orlova A, Nilsson FY, Wikman M et al (2006) Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. J Nucl Med 47:512-519
15. Engfeldt T, Tran T, Orlova A et al (2007) (99m)Tc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. Eur J Nucl Med Mol Imaging 18:1956-1964
16. Ahlgren S, Orlova A, Rosik D et al (2008) Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjug Chem 9:235-243
17. Orlova A, Tolmachev V, Pehrson R et al (2007) Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 67:2178-2186
18. HER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 47:846-853
19. 2:342), an Affibody ligand conjugate for targeting of HER2-expressing malignant tumors. Q J Nucl Med Mol Imaging 51:1-10
20. HER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. Int J Mol Med 19:285-291
21. 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 67:2773-2782
22. Baum R, Orlova A, Tolmachev V, Feldwisch J (2006) Receptor PET/CT and SPECT using an Affibody molecule for targeting and molecular imaging of HER2 positive cancer in animal xenografts and human breast cancer patients. J Nucl Med 47(Suppl):108P
23. Orlova A, Magnusson M, Eriksson TL et al (2006) Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 66:4339-4348
24. Steffen AC, Orlova A, Wikman M et al (2006) Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imaging 33:631-638
25. Steffen AC, Wikman M, Tolmachev V et al (2005) In vitro characterization of a bivalent anti-HER-2 affibody with potential for radio-nuclide-based diagnostics. Cancer Biother Radiopharm 20:239-248
26. Mume E, Orlova A, Larsson B et al (2005) Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjug Chem 16:1547-1555
27. 211At labeled HER-2 binding affibody molecules in mice. Oncol Rep 17:1141-1147
28. Gambhir SS (2002) Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2:683-693
29. Massoud TF, Gambhir SS (2003) Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17:545-580
30. Tolmachev V, Mume E, Sjöberg S, Frejd FY, Orlova A (2009) Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. Eur J Nucl Med Mol Imaging 36:692-701
31. Boswell CA, Sun X, Niu W, et al (2004) Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem 47:1465-1474
32. 99mTc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging 35:2245-2255
33. Ekerljung L, Steffen AC, Carlsson J, Lennartsson J (2006) Effects of HER2-binding affibody molecules on intracellular signaling pathways. Tumour Biol 27:201-210